藥物成份

共有 21645 個藥物成份

BUTETHAL SODIUM

• 關聯藥證數量: 1

BUTINOLIN

• 關聯藥證數量: 1

BUTORPHANOL TARTRATE

• 關聯藥證數量: 1

BUTOXYETHYL NICOTINATE

• 關聯藥證數量: 1

BUTYL-P-HYDROXYBENZOATE

• 關聯藥證數量: 1

BUTYLSCOPOLAMINE HBR

• 關聯藥證數量: 1

BUTYRIDIN

• 關聯藥證數量: 1

BaSO Liu Stain A: \nMethylene Blue (0.4g/L)、Eosin Y (2.3g/L).\nBaSO Liu Stain B:\nAzur I (1g/L)、Methylene Blue (0.4g/L)、Buffer (pH: 6.8±0.1)

• 關聯藥證數量: 1

BacT/ALERT MB-The media formulation consists of ： Middlebrook 7H9 Broth (0.47% w/v), Pancreatic Digest of Casein (0.1% w/v), Glycerol (0.1% w/v), SPS (0.025% w/v), in purified water.\nMB/BacT Enrichment Fluid-Bovine serum Albumin (14.5% w/v), Sodium Chloride (2.5% w/v), Oleic Acid (0.174% w/v), Saponin (4.4% w/v), in purified water. \n

• 關聯藥證數量: 1

BacT/ALERT MP-The media formulation consists of :Middlebrook 7H9 Broth,Pancreatic Digest of Casein,BSA,Catalase in purified water.\nMB-BacT Antibiotic Supplement-Lyophilized supplement formulated to contain Amphotericin B,Azolcilin,Nalidixic Acid,Polymyxin B,Trimethoprim,Vancomycin, and a bulking agent prior to processing.\nMB/BacT Reconstitution Fluid-Oleic acid,Glycerol,Amaranth,and BSA in purified water.

• 關聯藥證數量: 1

Bacillus Calmette-Guerin

• 關聯藥證數量: 1

Bacitracin 0.05units/disc

• 關聯藥證數量: 1

Bacitracin Zinc It has a potency of not less than 65 Bacitracin Units per mg (dried basis). It contains not less than 4.0~6.0% of zinc(Zn).(dried basis).

• 關聯藥證數量: 1

Bacitracin not less than 65 Bacitracin Units per mg (dried basis)

• 關聯藥證數量: 1

Baclofen contains not less than 98.0% and not more than 101.0 % of C10H12ClNO2, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Baclofen contains not less than 99.0 percent and not more than 101.0 percent of C10H12ClNO2, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Baclofen contains not less than 99.0% and not more than 101.0% of C10H12ClNO2, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Balsalazide Disodium Dihydrate contains not less than 98.0% and not more than 102.0% of C17H13N3Na2O6.2H2O, calculated on the as-is basis.

• 關聯藥證數量: 1

Bambuterol HCl contains not less than 98.5% and not more than 101.5% of C18H29N3O5。HCl calculated on anhydrous basis.

• 關聯藥證數量: 1

Barbiturates (secobarbital) 200 ng/mL\nBenzodiazepines (nordiazepam) 300 ng/mL\nCannabinoids (△9 THC-COOH) 50 ng/mL\nCocaine (benzoylecgonine) 150 ng/mL\nMethadone (dl-methadone) 300 ng/mL\nMethaqualone (methaqualone) 300 ng/mL\nOpiates (d-morphine) 2000 ng/mL\nPCP (phencyclidine) 25 ng/mL\nPropoxyphene (propoxyphene) 300 ng/mL\n

• 關聯藥證數量: 1

Basal medium: amino acids, inorganic salts, Vitamins.\nSupplement: sterile FBS. Recombinant growth factors.

• 關聯藥證數量: 1

Bead Pack 200 beads, coated with anti-ligand derived from streptavidin.\nReagent Wedge：11.5 mL ligand-labeled antigastrin murine monoclonal antibody, alkaline phosphatase(bovine calf intestine)conjugated to murine monoclonal anti-gastrin antibody, and alkaline phosphatase(bovine calf intestine) conjugated to rabbit polyclonal anti-gastrin, in buffer.\nAdjustors：Two vials (Low and High) of lyophilized synthetic human gastrin G-17 in a buffer matrix.\n

• 關聯藥證數量: 1

Bead Pack : 200 beads, coated with anti-ligand.\nReagent Wedge : 11.5mL ligand-labeled anti-CRP murine monoclonal antibody and alkaline phosphatase conjugated to rabbit polyclonal anti-CRP antibody in buffer.\nAdjustors : Two vials (Low and High), 2.0mL each, of CRP in a protein/buffer matrix.\nSample Diluent : For the on-board dilution of patient samples. 50mL of a concentrated CRP-free protein/buffer matrix.

• 關聯藥證數量: 1

Bead Pack: 200 beads, coated with anti-ligand. Reagent Wedge: 28 mL alkaline phosphatase (bovine calf intestine) conjugated to monoclonal murine antihuman IgE antibody in a human/nonhuman serum bueffer matrix. Adjustors: Two vials (Low and High), 2.0 mL each, of huamn IgE in a nonhuman serum matrix. Adjustor Antibody: Two tubes, 2.75 mL each of liquid, ligand-labeled polyclonal goat antihuman IgE antibody. Universal Kit Controls:Two vials, 2mL each of human IgE in a nonhuman serum matrix.Control Antibody: Two tubes, 2.75 mL each of liquid, ligand-labeled polyclonal goat antihuman IgE antibody.

• 關聯藥證數量: 1

Bead Pack: 200 beads, coated with anti-ligand.\nReagent Wedge: 11.5 mL of ligand-labeled anti-thyroglobulin murine monoclonal antibody and alkaline phosphatase (bovine calf intestine) conjugated to sheep polyclonal anti-thyroglobulin antibody in buffer, with preservative. \nAdjustors: Two vials (Low and High) of lyophilized thyroglobulin in a nonhuman serum matrix, with preservative.\nSample Diluent:thyroglobulin-free nonhuman serum matrix.

• 關聯藥證數量: 1

Bead Pack: 200 beads, coated with highly purified human TPO. Reagent Wedge: 11.5 mL buffer matrix, with preservative.11.5 mL alkaline phosphatase (bovine calf intestine) conjugated to monoclonal murine antihuman IgG in buffer, with preservative. Adjustors: Two vials (Low and High), of lyophilized TPO autoantibodies in a human serum/buffer matrix,with preservative. Sample diluent: 50 mL concentrated anti-TG/anti-TPO antibody-free buffer matrix, with preservative.

• 關聯藥證數量: 1

Bead Pack: 200 beads, coated with monoclonal murine anti-T3.\nReagent Wedge: 11.5 mL alkaline phosphatase conjugated to T3.\nAdjustors: Two vials (Low and High), of T3 in processed human serum.

• 關聯藥證數量: 1

Bead Pack: 200 beads, coated with monoclonal murine anti-digoxin. Reagent Wedge: Two reagents: 5.5 mL of alkaline phosphatase (bovine calf intestine) conjugated to digoxin, in buffer, and 11.5 mL of buffer. Adjustors: Two vials (Low and High), 2 mL each, of digoxin in human serum matrix.

• 關聯藥證數量: 1

Bead Pack: 200 beads, coated with monoclonal murine anti-valproic acid. Reagent Wedge: 11.5 ml alkaline phosphatase (bovine calf intestine) conjugated to 6-amino-2-propylhexanoic acid in buffer. Adjustors: two vials (Low and High), 2.0 ml each, of valproic acid in processed human serum.

• 關聯藥證數量: 1

Bead Pack: 200 beads, coated with polyclonal goat anti-β2-microglobulin.\n Reagent Wedge: 11.5 mL alkaline phosphatase (bovine calf intestine) conjugated to\n murine monoclonal anti-β2-microglobulin in buffer, with preservative. \nAdjustors: Two vials (Low and High) of lyophilized β2-Microglobulin in a synthetic matrix. \n

• 關聯藥證數量: 1

Bead Pack: 200 beads, coated with polyclonal rabbit anti-C-peptide.\nReagent Wedge: 17.5 mL alkaline phosphatase conjugated to C-peptide in buffer.\nAdjustors: Two vials (Low and High) of lyophilized C-peptide in buffered human albumin.

• 關聯藥證數量: 1

Bead Pack: 200 beads, coated with polyclonal rabbit anti-androstenedione antibody.\nReagent Wedge: 11.5 mL alkaline phosphatase (bovine calf intestine) conjugated to androstenedione in buffer. \nAdjustors: Two vials (Low and High), 2 mL each, of androstenedione in a processed human serum matrix.

• 關聯藥證數量: 1

Bead Pack: 200 beads, coated with polyclonal rabbit anti-digitoxin antibody.Reagent Wedge: 11.5 mL alkaline phosphatase (bovine calf intestine) conjugated to digitoxin in buffer.Adjustors: Two vials (Low and High), 4 mL each, of digitoxin in processed human serum, with preservative.

• 關聯藥證數量: 1

Bead Pack: 200 beads, coated with polyclonal rabbit anti-phenytoin antibody. Reagent Wedge: 21 ml alkaline phosphatase (bovine calf intestine) conjugated to phenytoin in buffer, with preservative, dispensed equally into chambers A and B. Adjustors: two vials (Low and High), 2.0 ml each, of phenytoin in processed human serum, with preservative.\n\n

• 關聯藥證數量: 1

Bead Pack: Rubella antigen, Reagent Wedge: bovine alkaline phosphase, murine MAB.\nAdjustors: human serum, Controls: human serum.

• 關聯藥證數量: 1

Bead Pack: With barcode. 200 beads, coated with monoclonal murine anti-myoglobin antibody.\nReagent Wedge: With barcode. 11.5 mL alkaline phosphatase (bovine calf intestine) conjugated to polyclonal goat antimyoglobin antibody in buffer.\nAdjustors: Two vials (Low and High) of lyophilized myoglobin in a nonhuman serum matrix.\n

• 關聯藥證數量: 1

Bead Pack: coated with monoclonal murine anti-carbamazepine antibody.Reagent Wedge: 11.5 mL alkaline phosphatase (bovine calf intestine) conjugated to alkaline phosphatase (bovine calf intestine) conjugated to carbamazepine in buffer, with preservative.Adjustors: Two vials (Low and High), 2.0 mL each, of carbamazepine in processed human serum, with preservative.

• 關聯藥證數量: 1

Bead Pack: coated with monoclonal murine anti-phenobarbital antibody. Reagent Wedge: 11.5 ml alkaline phosphatase (bovine calf intestine) conjugated to Phenobarbital in buffer. Adjustors: two vials (Low and High), 2 ml each, of Phenobarbital in human serum.

• 關聯藥證數量: 1

Bead Pack: coated with polyclonal rabbit anti-estriol.\nReagent Wedge: 11.5 mL alkaline phosphatase (bovine calf intestine) conjugated to estriol in buffer.\nAdjustors: Two vials (Low and High), 4 mL each, of unconjugated estriol in a processed human serum matrix.

• 關聯藥證數量: 1

Bead Pack: containing coated bead coated with murine monoclonal anti- IGFBP-3.\nReagent Wedge: 6.5 mL alkaline phosphatase conjugated to murine monoclonal anti- IGFBP-3 in buffer.\nAdjustors: Two vials (Low and High), of IGFBP-3 in a protein/buffer matrix. 100 mL anti-IGFBP-3 antibody-free protein/buffer matrix.

• 關聯藥證數量: 1

Bead Pack： 200 beads, coated with murine monoclonal anti-IGFBP-3.Reagent Wedge：11.5 mL alkaline phosphatase (bovine calf intestine) conjugated to murine monoclonal anti- IGFBP-3 in buffer.Adjustor：Two vials (Low and High), 4 mL each, of IGFBP-3 in a protein/buffer matrix. Sample Diluent：55 mL of concentrated IGFBP-3-free protein/buffer matrix.

• 關聯藥證數量: 1

Bead Pack：200 beads, coated with monoclonal murine anti-ferritin.\nReagent Wedge：11.5 mL alkaline phosphatase (bovine calf intestine) conjugated to polyclonal goat anti-ferritin in buffer, with preservative.\nAdjustors：Two vials (Low and High), 2.5 mL each, of ferritin in a human protein-based matrix, with preservative.

• 關聯藥證數量: 1

Bead Pack：200 beads, coated with monoclonal murine anti-myoglobin antibody.\nReagent Wedge：11.5 mL alkaline phosphatase (bovine calf intestine) conjugated to polyclonal goat anti-myoglobin antibody in buffer, with preservative.\nAdjustors：Two vials (Low and High) of lyophilized myoglobin in a nonhuman serum matrix, with preservative.

• 關聯藥證數量: 1

Bead Pack：200 beads, coated with murine monoclonal anti-hGH antibody.\nReagent Wedge：11.5 mL alkaline phosphatase conjugated to rabbit polyclonal anti-hGH antibody in buffer.\nAdjustors：Two vials (Low and High) containing lyophilized hGH in a nonhuman serum.

• 關聯藥證數量: 1

Bead-Oligo (1×1.6 mL)\nDNA oligo bound to streptavidin-coated paramagnetic beads. \nWT Probe (1×0.8 mL)\nRuthenium-labeled DNA oligo.\nSC Probe (1×0.8 mL)\nRuthenium-labeled DNA oligo.\nDetection diluent (1×1.7 mL)\nTRIS/HCl.\nInstrument Reference Solution (2×1.7 mL)\nRuthenium-labeled paramagnetic beads.

• 關聯藥證數量: 1

Becker titer: antigen protein concentration which reacts with 1 mL of antiserum specific antibodies.

• 關聯藥證數量: 1

Beckman Coulter Calibrator 5 Plus(CAL 5 Plus) 4x2mL vials Calibrator 5 Plus Bar Code Card 1 Calibrator 5 Plus Bar Code Strips 2

• 關聯藥證數量: 1

Beclomethasone Dipropionate contains not less than 96.0% and not more than the equivalent of 103.0% of C28H37ClO7, calculated with reference to the dried substance.

• 關聯藥證數量: 1

Beclomethasone Dipropionate contains not less than 97.0% percent and not more than 103.0 percent of C28H37ClO7, calculated on the dried basis.

• 關聯藥證數量: 1

Beclomethasone Dipropionate is anhydrous. It contains not less than 97.0 percent and not more than 103.0 percent of C28H37ClO7, calculated on the dried basis.

• 關聯藥證數量: 1

Beclomethasone Dipropionate is anhydrous.\nIt contains not less than 97.0 percent and not more than 103.0 percent of C28H37ClO7, calculated on the dried basis.

• 關聯藥證數量: 1

Beef Extract 2.0g\nAcid Hydrolysate of Casein 17.5g\nStarch 1.5g\nAgar 17g\nDist H2O 1000ml

• 關聯藥證數量: 1

Beef Extract 3g

• 關聯藥證數量: 1

Bempedoic Acid

• 關聯藥證數量: 1

Benazepril HCl contains not less than 98.0% and not more than 102.0% of C24H28N2O5˙HCl calculated on the dried basis.

• 關聯藥證數量: 1

Benproperine Phosphate contains not less than 98.5% of C21H27NO.H3PO4 calculated on the dried basis.

• 關聯藥證數量: 1

Benserazide HCl contains not less than 98.5% and not more than 101.0% of C10H16ClN3O5, calculated with reference to the anhydrous substance.

• 關聯藥證數量: 1

Benserazide Hydrochloride contains not less than 98.5% and not more than 101.0% of C10H16ClN3O5, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Benzarone contains not less than 99.0% and not more than 100.0% of C17H14O3, calculated on the dried basis.

• 關聯藥證數量: 1

Benzbromarone contains not less than 98.5% and not more than 101.0% of benzbromarone (C17H12Br2O3), calculated on the dried substance.

• 關聯藥證數量: 1

Benzbromarone contains not less than 98.5% of C17H12Br2O3 calculated on the dried basis.

• 關聯藥證數量: 1

Benzbromarone, when dried, contains not less than 98.0% and not more than 101.0% of C17H12Br2O3.

• 關聯藥證數量: 1

Benzethonium Chloride contains not less than 97.0% and not more than 103.0% of C27H42ClNO2, calcualted on the dried basis.

• 關聯藥證數量: 1

Benzocaine Definition Ethyl 4-aminobenzoate. Content: 99.0% to 101.0% (dried substance).

• 關聯藥證數量: 1

Benzocaine (standard grade) contains not less than 99.0 percent and not more than 101.0 percent of C9H11NO2, calculated on the dried substance.

• 關聯藥證數量: 1

Benzocaine contents 99.0% to 101.0% (dried substance)

• 關聯藥證數量: 1

Benzocaine, dried over phosphorus pentoxide for 3 hours, contains not less than 98.0 percent and not more than 102.0 percent of C9H11NO2.

• 關聯藥證數量: 1

Benzotriazole

• 關聯藥證數量: 1

Benzoyl Peroxide Hydrous contains not less than 90.0 % and not more than 110.0 % of C14H10O4. It contains a minimum of 20% of water.

• 關聯藥證數量: 1

Benzydamine HCl contains not less than 99.0% and not more than 101.0% of C19H23N3O, HCl calculated with reference to the dried substance.

• 關聯藥證數量: 1

Benzydamine Hydrochloride contains not less than 99.0% and not more than 101.0% of C19H23N3O, HCl, calculated with the dried substance.

• 關聯藥證數量: 1

Benzydamine Hydrochloride contains not less than 99.0% and not more than 101.0% of C19H23N3O,HCl, calculated with reference to the dried substance.

• 關聯藥證數量: 1

Benzylpenicillin Procaine contains not less than 96.0% and not more than 102.0% of C13 H20N2O2,C6H18N2O4S, and not less than 39.0% and not more than 42.0% of C13H20N2O2, both calculated with reference to the anhydrous substance.

• 關聯藥證數量: 1

Bepotastine Besilate 98.0%~102.0% (Anhydrous) (最終含量範圍)

• 關聯藥證數量: 1

Berberine Chloride contains not less than 95.0% and not more than 102.0% of C20H18ClNO4, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Berberine Hydrochloride contains not less than 95.0% and not more than 102.0% of C20H18ClNO4(mol. Wt.:371.841)，calculated on the anhydrous basis.

• 關聯藥證數量: 1

Berberine Sulfate 97-102%

• 關聯藥證數量: 1

Beta Carotene

• 關聯藥證數量: 1

Beta-2 Microglobulin Bead Pack (L2BM12)：beads coated with polyclonal goat anti-β2-microglobulin\nBeta-2 Microglobulin Reagent Wedge (L2BMA2)：alkaline phosphatase (bovine calf intestine) conjugated to murine monoclonal anti-β2-microglobulin in buffer.\nBeta-2 Microglobulin Adjustors (LBML, LBMH) \n (Low and High) of lyophilized β2-microglobulin in a synthetic matrix.

• 關聯藥證數量: 1

Betahistine Dihydrochloride (C8H12N2‧2HCl) contains 99.0 percent to 101.0 percent (dried substance).

• 關聯藥證數量: 1

Betahistine Dihydrochloride (betahistine hydrochloride) contains not less than 99.0% and not more than 101.0% of C8H12H2‧2HCl, calculated on the dried basis.

• 關聯藥證數量: 1

Betahistine Dihydrochloride contains 99.0% ~ 101.0% of C8H14Cl2N2 (dried substance).

• 關聯藥證數量: 1

Betahistine Dihydrochloride contains not less than 99.0% and not more than 101.0% of C8H14Cl2N2, calculated with dried substance.

• 關聯藥證數量: 1

Betahistine Mesylate (e.q. Betahistine Dimesilate) contains not less than 98.0% and not more than 101.0% of C10H20N2O6S2, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Betamethasone (Betamethasone contains not less than 97.0 percent and not more than 103.0 percent of C22H29FO5, calculated on the dried basis.)

• 關聯藥證數量: 1

Betamethasone Dipropionate contains not less than 97.0% and not more than 103% of C28H37FO7 calculated on the dried basis.

• 關聯藥證數量: 1

Betamethasone Dipropionate contains not less than 97.0% and not more than 103.0% of C28H37FO7, calculated on the dried basis.

• 關聯藥證數量: 1

Betamethasone Dipropionate contains not less than 97.0% percent and not more than 103.0% percent of C28H37FO7, calculated on the dried basis.

• 關聯藥證數量: 1

Betamethasone Dipropionate contains not less than 97.0%and not more than 103.0% of C28H37FO7,calculated on the dried basis.

• 關聯藥證數量: 1

Betamethasone Dipropionate contents 97.0% to 102.0% (dried substance).

• 關聯藥證數量: 1

Betamethasone Sodium Phosphate contains not less than 96.0 % and not more than 103.0 % of C22H28FNa2O8P,calculated on the dried basis.

• 關聯藥證數量: 1

Betamethasone Sodium Phosphate contains not less than 96.0% and not more than 103.0% of C22H28FNa2O8P calculated on dried basis.

• 關聯藥證數量: 1

Betamethasone Sodium Phosphate contains not less than 96.0% and not more than 103.0% of C22H28FNa2O8P calculated on the dried basis.

• 關聯藥證數量: 1

Betamethasone Sodium Phosphate contains not less than 96.0% and not more than 103.0% of C22H28FNa2O8P, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Betamethasone Sodium Phosphate contains not less than 96.0% and not more than 103.0% of C22H28FNa2O8P, calculated on the dried basis.

• 關聯藥證數量: 1

Betamethasone Sodium Phosphate contains not less than 97.0 percent and not more than 103.0 percent of C22H28FNa2O8P, calcualted on the anhydrous basis.

• 關聯藥證數量: 1

Betamethasone Sodium Phosphate contains not less than 97.0 percent and not more than 103.0 percent of C22H28FNa2O8P, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Betamethasone Sodium Phosphate contents 96.0% to 103.0% (anhydrous substance).

• 關聯藥證數量: 1

Betamethasone Valerate contains not less than 97.0 % and not more than 103.0 % of C27H37FO6,calculated on the dried basis.

• 關聯藥證數量: 1

Betamethasone Valerate contains not less than 97.0 percent and not more than 103.0 percent of C27H37FO6, calculated on the dried basis.

• 關聯藥證數量: 1